147159-51-1
147159-51-1
Chemical Structure
TT-232
Synonym(s): CAP-232; TLN-232
- CAS No.: 147159-51-1
- Formula:C45H58N10O9S2
- Molecular Weight:947.13
IUPAC Name: (4R,7S,10R,13S,16R)-10-((1H-indol-3-yl)methyl)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-16-((R)-2-amino-3-phenylpropanamido)-7-(4-aminobutyl)-13-(4-hydroxybenzyl)-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetraazacycloheptadecane-4-carboxamide
InChIKey: SNAJPQVDGYDQSW-DYCFWDQMSA-N
SMILES: O=C(N[C@H](C(N[C@@H]1C(N[C@H](C(N)=O)[C@H](O)C)=O)=O)CCCCN)[C@H](NC([C@@H](NC([C@H](CSSC1)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC(C=C3)=CC=C3O)=O)CC4=CNC5=CC=CC=C45
Biological Activity: TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent[1][2][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TT-232 | 98.72% | TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TT-232 TFA | TT-232 TFA (CAP-232 TFA) is an analogue of somatostatin. TT-232 TFA can induce apoptosis of pancreatic tumor cell lines, inhibit tyrosine kinase activity and stimulate tyrosine phosphatase activity in colon tumor cell lines. TT-232 TFA inhibits the proliferation of tumor cells, induces apoptosis of tumor cells and shows strong anti-tumor effects. TT-232 TFA can be used in the development of anti-tumor drugs and the study of apoptosis mechanism. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Octreotide | 99.96% | Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Octreotide dihydrochloride | Octreotide (SMS 201-995) hydrochloride is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide hydrochloride can bind to the somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide hydrochloride increases Gi activity and reduces intracellular cAMP production. Octreotide hydrochloride has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tyr3-Octreotate | 99.76% | Tyr3-Octreotate is a ligand for somatostatin receptor subtype 2 (sst2), with an IC50 value of 1.3 nM against sst2 when labeled with [111In-DTPA], and an IC50 value of 1.6 nM against sst2 when labeled with [90Y-DOTA]. Radiolabeled Tyr3-Octreotate generates cell-associated radioactivity, and acts as both a tumor growth inhibitor and a tumor cytotoxic agent. When radiolabeled with 177Lu or 90Y, Tyr3-Octreotate serves as a peptide receptor radionuclide therapy (PRRT) analog. Tyr3-Octreotate can be used in studies related to pancreatic tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Des-threoninol-octreotide | Des-threoninol-octreotide (Compound 13) is a Somatostatin analog. Des-threoninol-octreotide inhibits cloned somatostatin receptors with IC50 values of 13.62 nM, 10.63 nM, 10.95 nM for mSSTR2b, rSSTR5 and hSSTR5, respectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Urotensin II-related peptide | 99.52% | Urotensin II-related peptide is a human urotensin II anague. Urotensin II-related peptide has high affinity for the UT receptor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SDZ 204-090 | ||||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lanreotide | 98.86% | Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lanreotide acetate | 99.78% | Lanreotide (BIM 23014) acetate is a somatostatin analogue with antineoplastic activity. Lanreotide acetate can be used for the research of carcinoid syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nendratareotide | Nendratareotide is a somatostatin analogue. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Szende B, et al. TT-232: a somatostatin structural derivative as a potent antitumor drug candidate. Anticancer Drugs. 2003 Sep;14(8):585-8. [Content Brief]
- [2]. Kéri G, et al. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12513-8. [Content Brief]
- [4]. Pintér E, et al. Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia. Naunyn Schmiedebergs Arch Pharmacol. 2002 Aug;366(2):142-50. [Content Brief]
